FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980302108> ?p ?o ?g. }

• W2980302108 abstract "Abstract B cell chronic lymphocytic leukemia (CLL) can be stratified into indolent and aggressive subtypes according to the degree of somatic hypermutation evident in the immunoglobulin heavy chain variable region gene (IGHV). Despite some discordance with IGHV mutation status, both CD38 and ZAP-70 are routinely analyzed in clinical practice and are considered useful prognostic factors for segregating patients with aggressive-unmutated CLL (U-CLL). Members of the Fc receptor-like (FCRL1-5) family have immunoregulatory function and are preferentially expressed by B cells. Their distinct distribution pattern among subsets in healthy donors suggests that the FCRLs may also have useful diagnostic and/or therapeutic potential in B lineage malignancies. Previous work employing a receptor-specific monoclonal antibody (mAb-7F2) and an indirect staining method demonstrated that FCRL2 is particularly upregulated on the surface of indolent-mutated CLL (M-CLL) cells. Among 107 CLL samples, 52 U-CLL and 55 M-CLL, FCRL2 overlapped with IGHV status with 94.4% concordance, relative to 76.6% for CD38 (cutoff of 30%), and 80.4% for ZAP-70 according to the T/B ratio (cutoff of 4.0) or 74.8% by the % method (cutoff of 20%). Because several years have passed since our initial analysis using this reagent, we updated the clinical information to reassess the relationship among these prognostic parameters with FCRL2 staining and to further determine the usefulness of this biomarker in CLL. Similar to IGHV status [Hazard ratio (HR)=5.03], FCRL2 could also, but more powerfully, predict survival (HR=8.58). Both these features were superior to CD38 (HR=1.29) and ZAP-70 by either the T/B ratio (HR=1.42) or % (HR=1.04) approaches. The median survival for FCRL2 positive cases was 26.2 years and for FCRL2 negative donors was 12.7 years. With regard to disease progression, FCRL2 positive cases had a median treatment free interval of 13.5 years, whereas for FCRL2 negative donors it was only 3.2 years. Given these promising results, we pursued optimizing FCRL2 detection and assayability by flow cytometry to validate its clinical utility for diagnostic and prognostic purposes in CLL. A screen of FCRL2-specific mAbs led to the identification of a novel subclone termed 3E11, which by epitope mapping reacted with a site discrete from that of 7F2. The binding kinetics of these two mAbs also differed. According to surface plasmon resonance studies using an FCRL2-Fc recombinant protein, 3E11 possessed ∼2.5X better nanomolar affinity and a slower dissociation rate than 7F2. The superiority of 3E11 was also evidenced by its relatively stronger surface staining reactivity in flow cytometry analyses. To achieve a one-step staining strategy, 3E11 was directly conjugated with PE. Use of this PE-labeled reagent demonstrated brighter and more selective FCRL2 reactivity on M-CLL versus U-CLL (N=30) cells using either the post-Ficoll or whole blood-lysis preparation methods. Importantly, its reactivity was also stable over time (Concordance Correlation Coefficient of 0.9). As a promising CLL biomarker capable of selectively detecting the MT-CLL subtype and predicting disease progression and survival, the current findings demonstrate the practicability and reliability of a newfound mAb for validating the prognostic value of FCRL2 in CLL. Disclosures: LI: University of Alabama at Birmingham: Filed Patent, Filed Patent Patents & Royalties. Davis:NIH an University of Alabama at Birmingham: Patent Filed, Patent Filed Patents & Royalties, Research Funding." @default.
• W2980302108 created "2019-10-18" @default.
• W2980302108 creator A5004741842 @default.
• W2980302108 creator A5012147802 @default.
• W2980302108 creator A5017675148 @default.
• W2980302108 creator A5031003109 @default.
• W2980302108 creator A5040500242 @default.
• W2980302108 creator A5068176076 @default.
• W2980302108 creator A5079531447 @default.
• W2980302108 date "2013-11-15" @default.
• W2980302108 modified "2023-09-27" @default.
• W2980302108 title "Validating The Prognostic Significance Of FCRL2 In Predicting IGHV Mutation Status, Clinical Disease Progression, and Survival In CLL" @default.
• W2980302108 doi "https://doi.org/10.1182/blood.v122.21.4140.4140" @default.
• W2980302108 hasPublicationYear "2013" @default.
• W2980302108 type Work @default.
• W2980302108 sameAs 2980302108 @default.
• W2980302108 citedByCount "1" @default.
• W2980302108 countsByYear W29803021082016 @default.
• W2980302108 crossrefType "journal-article" @default.
• W2980302108 hasAuthorship W2980302108A5004741842 @default.
• W2980302108 hasAuthorship W2980302108A5012147802 @default.
• W2980302108 hasAuthorship W2980302108A5017675148 @default.
• W2980302108 hasAuthorship W2980302108A5031003109 @default.
• W2980302108 hasAuthorship W2980302108A5040500242 @default.
• W2980302108 hasAuthorship W2980302108A5068176076 @default.
• W2980302108 hasAuthorship W2980302108A5079531447 @default.
• W2980302108 hasConcept C10205521 @default.
• W2980302108 hasConcept C126322002 @default.
• W2980302108 hasConcept C128526571 @default.
• W2980302108 hasConcept C143998085 @default.
• W2980302108 hasConcept C159654299 @default.
• W2980302108 hasConcept C159912055 @default.
• W2980302108 hasConcept C160798450 @default.
• W2980302108 hasConcept C194409129 @default.
• W2980302108 hasConcept C203014093 @default.
• W2980302108 hasConcept C2777609679 @default.
• W2980302108 hasConcept C2777938653 @default.
• W2980302108 hasConcept C2778453870 @default.
• W2980302108 hasConcept C2778461978 @default.
• W2980302108 hasConcept C28328180 @default.
• W2980302108 hasConcept C502942594 @default.
• W2980302108 hasConcept C54355233 @default.
• W2980302108 hasConcept C71924100 @default.
• W2980302108 hasConcept C86803240 @default.
• W2980302108 hasConceptScore W2980302108C10205521 @default.
• W2980302108 hasConceptScore W2980302108C126322002 @default.
• W2980302108 hasConceptScore W2980302108C128526571 @default.
• W2980302108 hasConceptScore W2980302108C143998085 @default.
• W2980302108 hasConceptScore W2980302108C159654299 @default.
• W2980302108 hasConceptScore W2980302108C159912055 @default.
• W2980302108 hasConceptScore W2980302108C160798450 @default.
• W2980302108 hasConceptScore W2980302108C194409129 @default.
• W2980302108 hasConceptScore W2980302108C203014093 @default.
• W2980302108 hasConceptScore W2980302108C2777609679 @default.
• W2980302108 hasConceptScore W2980302108C2777938653 @default.
• W2980302108 hasConceptScore W2980302108C2778453870 @default.
• W2980302108 hasConceptScore W2980302108C2778461978 @default.
• W2980302108 hasConceptScore W2980302108C28328180 @default.
• W2980302108 hasConceptScore W2980302108C502942594 @default.
• W2980302108 hasConceptScore W2980302108C54355233 @default.
• W2980302108 hasConceptScore W2980302108C71924100 @default.
• W2980302108 hasConceptScore W2980302108C86803240 @default.
• W2980302108 hasLocation W29803021081 @default.
• W2980302108 hasOpenAccess W2980302108 @default.
• W2980302108 hasPrimaryLocation W29803021081 @default.
• W2980302108 hasRelatedWork W1997879186 @default.
• W2980302108 hasRelatedWork W2051321376 @default.
• W2980302108 hasRelatedWork W2055377144 @default.
• W2980302108 hasRelatedWork W2061870054 @default.
• W2980302108 hasRelatedWork W2086152189 @default.
• W2980302108 hasRelatedWork W2156867352 @default.
• W2980302108 hasRelatedWork W2162106495 @default.
• W2980302108 hasRelatedWork W2171033786 @default.
• W2980302108 hasRelatedWork W2247337826 @default.
• W2980302108 hasRelatedWork W2428539785 @default.
• W2980302108 hasRelatedWork W243652188 @default.
• W2980302108 hasRelatedWork W2467363333 @default.
• W2980302108 hasRelatedWork W2513719242 @default.
• W2980302108 hasRelatedWork W2527149989 @default.
• W2980302108 hasRelatedWork W2537887569 @default.
• W2980302108 hasRelatedWork W2558062410 @default.
• W2980302108 hasRelatedWork W2588820075 @default.
• W2980302108 hasRelatedWork W2979558239 @default.
• W2980302108 hasRelatedWork W3133613713 @default.
• W2980302108 hasRelatedWork W3208075718 @default.
• W2980302108 isParatext "false" @default.
• W2980302108 isRetracted "false" @default.
• W2980302108 magId "2980302108" @default.
• W2980302108 workType "article" @default.